Enel S p A: opens a new innovation lab in Tel Aviv for artificial intelligence and robotics in renewables and power grids

AVRA MEDICAL ROBOTICS, INC. Discuss management and analyze the financial condition and results of operations. (form 10-K)

Results of Operations



Introduction


The financial statements appearing elsewhere in this prospectus have been prepared on the assumption that the Company will continue to operate on a going concern basis. The company was formed recently and has not created enough operations or revenue to support the company. These circumstances cast significant doubt about the Company’s ability to continue as a going concern.

The following table provides selected financial data about our company in
December 31, 2020 And the December 31, 2019:



Balance Sheet Data                As of              As of
                               December 31,       December 31,
                                   2021               2020
Cash                          $      405,774     $      160,709
Total Assets                  $      428,607     $      317,870
Total Liabilities             $      287,281     $    1,186,919
Total Stockholders' Deficit   $      141,326     $     (869,049 )



So far, the company has relied on debt and equity acquired in private offerings to fund operations and no other source of capital has been identified or sought. If we are faced with a shortage of operating capital, we may face the necessity of limiting our R&D and marketing activities.

The year is over December 31, 2021compared to the year ended December 31, 2020

Revenues. We have had no returns during the outgoing years December 31, 2021And the
December 31, 2020.

Research and development expenditures. Research and development expenses during the year ended December 31, 2021 they were 1000 dollarsCompared to 3000 Dollars for the year ending
December 31, 2020. Research and development expenditures reflect ongoing development work on the company’s modular robotic system at its facilities in the UCF incubator in Orlando Florida.

Compensation expenses. We had a compensation account $947,237 And the $812,190
During the year ending 2021 and 2020, respectively. This includes management employee compensation and stock-based compensation expense related to the company’s 2016 inventory incentive plan.



                                       16




General and administrative expenses. we incurred 458801 dollars in general and administrative expenses during the year ended December 31, 2021Compared to
$287,737 for the year ending December 31, 2020. General and administrative expenses include legal and other professional expenses related to the company’s files as a public company with Securities and Exchange Commission (Supreme Education Council”).

Other income (expenses). We won $118 During the year ending in 2021, compared to a net negative of $(21,754) During 2020. The net negative figure for 2020 is mainly attributable to the investment loss, which is partially offset by the PPP loan waiver.

net loss. We incurred a net loss of $1,484,313) for 2021 compared to a net loss of $1,124,681) For the year 2020. The increase in net loss from 2021 to 2020 is mainly due to the increase in general, administrative and compensation expenses.

Liquidity and capital resources

The company expects to request significant research and development funds, to further develop its initial proposed medical robotic system. The Company plans to meet its operating cash flow requirements by raising additional funds from the sale of our securities and, if possible, on favorable terms, by entering into development partnerships to assist the Company in its technology development activities.

during the period of incorporation (February 4, 2015) Across December 31, 2019Company raised (A) 1900 dollars From an initial private placement of its common shares in February 2017; (B) 480 thousand dollars From the private placement of convertible bonds completed in June 2017; (c) $135,000 From a private placement of 135,000 shares of common stock at a price $1.00 For each completed share in
February 2017; (Dr) $54,260 From a private placement of 438,808 shares of stock in a private placement at a price $1.25 For each completed share in September 2017; and (e) $20,000 From the private sale of 16,000 shares of our common stock at $1.25 per share in August 2018.

in March 2019the Company sold 7.5 units in a private placement of ten (10) units (“Units”), each unit consisting of a $10,000 The principal amount of a six-month promissory note with interest at 5% per annum and a three-year note to purchase 5,000 shares of common stock at an exercise price of $1.25
for each share.

In addition to the above, from December 2018 through October 2020The company obtained sixteen loans from Barry F Cohenour total CEO
$497.700. The loans were payable for 12 months from the date of financing and did not carry interest. Except for two loans in total 145,000 dollarsall such loans were subsequently repaid in full by conversion into restricted shares or units of the company including one loan to $100,000 that were used to exercise the stock option for the 1,000,000 shares owned by Mr. Cohen.

on me October 26, 2020AVRA has issued a total of 256,027 units (“Units”) at a price of $1.00 For each Unit in a private placement (“Offering”) to four “Accredited Investors”. Each unit consists of (a) four shares of our common stock (“Shares”); (B) A three-year guarantee to purchase five shares at the exercise price 0.40 USD per share and (c) the option to put up their membership units in Avra Aviation LLC For one share of our regular stock. As a result of the above, a total of 1,024,108 shares were issued, which included the purchase of 1,280,135 shares and the offering of options to put up 256,027 shares.

on me December 22, 2020 One Certified Investor and Invested CEO $25,000 And the
$202,700respectively, to 227,700 units at a price of $1.00 for each unit in a special subtraction (“subtraction”). Each unit consists of (a) four shares of our common stock; and (b) a three-year guarantee to purchase five shares at the exercise price 0.40 USD for each share. As a result of the above, a total of 910,800 shares were issued, and 1,138,500 shares were warranted. The CEO used a total of $202,700 of the bonds owed to him by the company to purchase these units.

on me February 10, 2020AVRA has issued a total of 235,000 units (“Units”) at $1.00 For each Unit in a private placement (“Offering”) to four “Accredited Investors”. Each unit consists of (a) four shares of our common stock (“Shares”); (B) A three-year guarantee to purchase five shares at the exercise price 0.40 USD for each share. As a result of the above, investors issued a total of 940,000 shares.





                                       17




between October 5, 2021 And the December 8, 2021 The company sold a total of 2,229,231 shares of common stock at prices ranging from $0.13 And the
$0.52 for each share. The company received revenue $315,200.

Although we have been successful in raising funds to fund our operations from the start and believe we will be successful in obtaining the funding needed to fund our operations in the future, we do not have any committed funding sources and no assurances that we will be able to secure additional funding. The accompanying financial statements have been prepared on the assumption that the Company will continue to operate on a going concern basis; However, if the above efforts are not successful, it will raise a fundamental doubt about the company’s ability to continue as a going concern. If we can’t get funding, we may have to further downsize our operations or consider other strategic alternatives. Even if we succeed in raising the additional funding, there is no guarantee as to the terms of any additional investment and any such investment or other strategic alternative is likely to significantly impair our existing shareholders.



Critical Accounting Policies



Use of Estimates


Preparing financial statements in accordance with generally accepted accounting principles United State Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of income and expenses during the reporting period. Actual results may differ from those estimates. Significant estimates include deferred revenue, costs incurred in connection with deferred revenue, useful lives of property and equipment and useful lives of intangible assets.




Income Taxes



The company calculates income taxes in accordance with ASC 740, Accounting for Income Taxes, as described in ASC 740-10, Accounting for Uncertainty in Income Taxes. Under this method, deferred income taxes are determined on the basis of the estimated future tax effects of the differences between the financial statements and the tax basis of assets and liabilities in accordance with the provisions of applicable tax laws. Deferred income tax provisions and benefits are based on changes in assets or liabilities from year to year. In making a provision for deferred tax, a company takes into account tax regulations in the countries in which the company operates, estimates of future taxable income, and available tax planning strategies. If tax regulations, operating results, or the ability to implement tax planning strategies differ, adjustments may be required to the carrying amount of deferred tax assets and liabilities. Valuation provisions relating to deferred tax assets are recorded based on the “more likely” criteria in ASC 740.

ASC 740-10 requires that a company recognize the benefits of a tax position financial statement only after determining that the relevant tax authority is likely to maintain the position after an audit. For tax centers that meet the “most likely or not” threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent probability of realizing on final settlement with the relevant IRS.

Balance Sheet Arrangements

There are no off-balance sheet arrangements that have or are reasonably likely to have a current or future impact on our financial position, or changes in financial position, revenue or expenses, results of operations, liquidity, capital expenditures or capital resources that are material For us. investors.

© Edgar Online, The Source glimpses

#AVRA #MEDICAL #ROBOTICS #Discuss #management #analyze #financial #condition #results #operations #form #10K

Leave a Comment

Your email address will not be published. Required fields are marked *